{"id":"https://openalex.org/W4416679883","doi":"https://doi.org/10.1158/0008-5472.30702253","title":"Supplementary Data from Temozolomide Sensitizes ARID1A-Mutated Cancers to PARP Inhibitors","display_name":"Supplementary Data from Temozolomide Sensitizes ARID1A-Mutated Cancers to PARP Inhibitors","publication_year":2025,"publication_date":"2025-11-25","ids":{"openalex":"https://openalex.org/W4416679883","doi":"https://doi.org/10.1158/0008-5472.30702253"},"language":null,"primary_location":{"id":"doi:10.1158/0008-5472.30702253","doi":"https://doi.org/10.1158/0008-5472.30702253","is_oa":true,"landing_page_url":"https://doi.org/10.1158/0008-5472.30702253","pdf_url":"https://aacr.figshare.com/articles/journal_contribution/Supplementary_Data_from_Temozolomide_Sensitizes_i_ARID1A_i_-Mutated_Cancers_to_PARP_Inhibitors/30702253/1/files/59816404.pdf","source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"volume":null,"type":"supplementary-materials","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://aacr.figshare.com/articles/journal_contribution/Supplementary_Data_from_Temozolomide_Sensitizes_i_ARID1A_i_-Mutated_Cancers_to_PARP_Inhibitors/30702253/1/files/59816404.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5040641751","display_name":"Zheng-Cheng Yu","orcid":"https://orcid.org/0000-0002-1908-9266","observed_orcids":["https://orcid.org/0000-0002-1908-9266"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Zheng-Cheng Yu","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-1908-9266","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5076450457","display_name":"Tianhe Li","orcid":"https://orcid.org/0009-0006-5525-9070","observed_orcids":["https://orcid.org/0009-0006-5525-9070"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Tianhe Li","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0009-0006-5525-9070","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068161745","display_name":"Ellen Tully","orcid":"https://orcid.org/0000-0001-5574-0717","observed_orcids":["https://orcid.org/0000-0001-5574-0717"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ellen Tully","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-5574-0717","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5021960666","display_name":"Peng Huang","orcid":"https://orcid.org/0000-0002-8678-8999","observed_orcids":["https://orcid.org/0000-0002-8678-8999"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Peng Huang","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-8678-8999","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5013577711","display_name":"Chih\u2010Ning Chen","orcid":"https://orcid.org/0000-0002-3274-3488","observed_orcids":["https://orcid.org/0000-0002-3274-3488"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Chih-Ning Chen","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-3274-3488","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5044014965","display_name":"Philipp Oberdoerffer","orcid":"https://orcid.org/0000-0002-2484-1440","observed_orcids":["https://orcid.org/0000-0002-2484-1440"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Philipp Oberdoerffer","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-2484-1440","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5031348375","display_name":"Stephanie L. Gaillard","orcid":"https://orcid.org/0000-0002-2174-3693","observed_orcids":["https://orcid.org/0000-0002-2174-3693"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Stephanie Gaillard","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-2174-3693","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5058026421","display_name":"Ie\u2010Ming Shih","orcid":"https://orcid.org/0000-0002-1084-2071","observed_orcids":["https://orcid.org/0000-0002-1084-2071"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ie-Ming Shih","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-1084-2071","affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5058741744","display_name":"Tian\u2010Li Wang","orcid":"https://orcid.org/0000-0002-7082-449X","observed_orcids":["https://orcid.org/0000-0002-7082-449X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Tian-Li Wang","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-7082-449X","affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11914","display_name":"PARP inhibition in cancer therapy","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11914","display_name":"PARP inhibition in cancer therapy","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12820","display_name":"Chromatin Remodeling and Cancer","score":0.0017000000225380063,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10129","display_name":"Glioma Diagnosis and Treatment","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/temozolomide","display_name":"temozolomide","score":1.0},{"id":"https://openalex.org/keywords/arid1a-mutation","display_name":"ARID1A mutation","score":0.9340000152587891},{"id":"https://openalex.org/keywords/parp-inhibitors","display_name":"PARP inhibitors","score":0.9990000128746033},{"id":"https://openalex.org/keywords/drug-sensitization","display_name":"drug sensitization","score":0.6269999742507935},{"id":"https://openalex.org/keywords/dna-repair","display_name":"DNA repair","score":0.5270000100135803},{"id":"https://openalex.org/keywords/cancer-therapy","display_name":"cancer therapy","score":0.5450000166893005}],"concepts":[{"id":"https://openalex.org/C2777389519","wikidata":"https://www.wikidata.org/wiki/Q425088","display_name":"Temozolomide","level":3,"score":0.7229999899864197},{"id":"https://openalex.org/C182979987","wikidata":"https://www.wikidata.org/wiki/Q3907241","display_name":"Poly ADP ribose polymerase","level":4,"score":0.6244000196456909},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5659999847412109},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5159000158309937},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.30489999055862427},{"id":"https://openalex.org/C143425029","wikidata":"https://www.wikidata.org/wiki/Q5205747","display_name":"DNA damage","level":3,"score":0.2937999963760376},{"id":"https://openalex.org/C2779138821","wikidata":"https://www.wikidata.org/wiki/Q7118227","display_name":"PARP inhibitor","level":5,"score":0.2824000120162964},{"id":"https://openalex.org/C134935766","wikidata":"https://www.wikidata.org/wiki/Q210538","display_name":"DNA repair","level":3,"score":0.2750999927520752},{"id":"https://openalex.org/C2779962180","wikidata":"https://www.wikidata.org/wiki/Q7083106","display_name":"Olaparib","level":5,"score":0.2702000141143799},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.24959999322891235}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.1158/0008-5472.30702253","doi":"https://doi.org/10.1158/0008-5472.30702253","is_oa":true,"landing_page_url":"https://doi.org/10.1158/0008-5472.30702253","pdf_url":"https://aacr.figshare.com/articles/journal_contribution/Supplementary_Data_from_Temozolomide_Sensitizes_i_ARID1A_i_-Mutated_Cancers_to_PARP_Inhibitors/30702253/1/files/59816404.pdf","source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},{"id":"pmh:oai:figshare.com:article/30702253","doi":null,"is_oa":true,"landing_page_url":"https://figshare.com/articles/journal_contribution/Supplementary_Data_from_Temozolomide_Sensitizes_i_ARID1A_i_-Mutated_Cancers_to_PARP_Inhibitors/30702253","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"Text"}],"best_oa_location":{"id":"doi:10.1158/0008-5472.30702253","doi":"https://doi.org/10.1158/0008-5472.30702253","is_oa":true,"landing_page_url":"https://doi.org/10.1158/0008-5472.30702253","pdf_url":"https://aacr.figshare.com/articles/journal_contribution/Supplementary_Data_from_Temozolomide_Sensitizes_i_ARID1A_i_-Mutated_Cancers_to_PARP_Inhibitors/30702253/1/files/59816404.pdf","source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.5683000087738037}],"sustainable_development_goals_aurora":[],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4416679883.pdf","grobid_xml":"https://content.openalex.org/works/W4416679883.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":[],"abstract_inverted_index":{"Supplementary":[0],"Figures":[1]},"counts_by_year":[],"updated_date":"2026-10-01T08:54:57.152042","created_date":"2025-11-25T00:00:00"}